In the context of the innovative and emerging two-step anticancer therapeutic concept, that first evokes senescence and then eliminates residual senescent cancer cells with senolytic agents [55,56], combining volasertib with radiotherapy to prime patients with functional p53 for senolytic agents could be a promising new treatment strategy to ultimately maximize therapeutic efficiency and patient outcome. This evidence concerns the gene TP53 and cancer.